TICKERNERD
Menu
DCTHDCTHHealthcare · Medical Devices

DCTH Stock Forecast: Delcath Systems, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$14
−4.10% on the day

The 5 Wall Street analysts covering Delcath Systems, Inc. hold a median 12-month price target of $22 — +56.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 31 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$487.2M
Ticker Nerd rank
96/ 100
Median analyst target
$22
Analysts covering
5
Revenue$29.1M+20.6% y/y
Operating income$2.4M
Net income$2.7M
Free cash flow$5.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.6%
1M
−12.1%
YTD
+39.0%
1Y
+49.4%
From 52W high
−19.1%
From 52W low
+71.4%
$8
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DCTH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Delcath Systems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
96/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
100
Value
99
Revisions
91
Momentum
78
Accruals
77
Volatility
70
Size
53
Issuance
39
Growth
36

Quality (100): The business earns solid, repeatable profits on what it owns.

Growth (36): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

DCTH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DCTH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26DCTHHigh $32Median $22Low $21

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $21Median $22High $32

The green dot is the last close — the median target sits +56.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
7 Aug 2026HC Wainwright & Co.MaintainsBuy$30 → $32
6 Aug 2026BTIGMaintainsBuy$17 → $21
26 Feb 2026BTIGMaintainsBuy—
26 Feb 2026BTIGMaintainsBuy$23 → $19
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
5 Nov 2025Stephens & Co.MaintainsOverweight—
4 Nov 2025BTIGReiteratesBuy—
21 Oct 2025Canaccord GenuityMaintainsBuy—
20 Oct 2025HC Wainwright & Co.MaintainsBuy—
7 Aug 2025HC Wainwright & Co.MaintainsBuy—
23 June 2025Stephens & Co.ReiteratesOverweight—
23 May 2025HC Wainwright & Co.MaintainsBuy—
7 Mar 2025HC Wainwright & Co.MaintainsBuy—
17 Jan 2025Craig-HallumMaintainsBuy—
14 Jan 2025HC Wainwright & Co.ReiteratesBuy—
11 Nov 2024HC Wainwright & Co.ReiteratesBuy—
18 Oct 2024Canaccord GenuityMaintainsBuy$21
18 Oct 2024HC Wainwright & Co.ReiteratesBuy$22
6 Aug 2024HC Wainwright & Co.ReiteratesBuy—
6 Aug 2024Stephens & Co.ReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

DCTH appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

DCTH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Delcath Systems, Inc. returned +49.4% against +12.4% for the S&P 500, dividends included.

DCTH vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26DCTHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DCTH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
5
Fundamentals

Delcath Systems, Inc. (DCTH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1404.0×

Cheaper than 1% of US stocks

Price / sales
5.1×

Cheaper than 23% of US stocks

Price / book
4.0×

Cheaper than 23% of US stocks

EV / EBITDA
−270.6×

Cheaper than 98% of US stocks

Growth & margins
Revenue growth (YoY)
20.6%

Higher than 70% of US stocks

Earnings growth (YoY)
−1.1%

Higher than 35% of US stocks

Gross margin
89.8%

Higher than 96% of US stocks

Operating margin
8.2%

Higher than 61% of US stocks

Net margin
0.6%

Higher than 48% of US stocks

Returns & dividend
Return on equity
0.5%

Higher than 45% of US stocks

Return on assets
−0.9%

Higher than 40% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Delcath Systems, Inc. (DCTH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Delcath Systems, Inc. has a market value of $487.2M and an enterprise value of $393.7M.

  • Revenue in the twelve months to 30 June 2026: $95.4M. The latest quarter grew 20.6% year on year.

  • Net income over the same four quarters: $532K, a 0.6% net margin.

  • Diluted earnings per share, trailing twelve months: $0.01.

  • Free cash flow in the twelve months to 30 June 2026: $17.5M.

  • Shares outstanding: 34.6M.

  • Trailing P/E: 1404.0×; forward P/E: 312.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Delcath Systems, Inc. employs 156 people — $612K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

DCTH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
DCTHDelcath Systems, Inc.$487.2M96
RCELAVITA Medical, Inc.$484.0M71
SENSSenseonics Holdings, Inc.$496.5M29
SGHTSight Sciences, Inc.$503.3M88
MASS908 Devices, Inc.$461.6M80
SSIISS Innovations International, Inc.$455.0M24
TCMDTactile Systems Technology, Inc.$519.7M99

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Delcath Systems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DCTH news & analysis

Delcath Systems to Participate in Upcoming Investor Conferences

Business Wire · 27 Oct 2026neutral

Delcath Systems announced that management will attend the UBS Global Healthcare Conference on November 10, 2026, in Palm Beach Gardens, and Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026, in New York. The excerpt also begins listing another conference but does not provide its details.

Why it matters — Investors can note the scheduled opportunities for management to participate in healthcare and medtech investor conferences.

Delcath Systems to Host Third Quarter 2026 Earnings Call

Business Wire · 26 Oct 2026neutral

Delcath Systems announced it will host a conference call on November 9, 2026, at 8:30 a.m. Eastern Time to discuss results for the third quarter ended September 30, 2026.

Why it matters — The call will provide DCTH watchers with an opportunity to hear the company discuss its third-quarter results.

Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Business Wire · 19 Oct 2026positive

Delcath Systems announced clinical development program presentations at the ESMO Congress 2026 in Madrid, and highlighted publication of an independent, investigator-led analysis of percutaneous hepatic perfusion.

Why it matters — The presentations and independent analysis provide updates on Delcath’s clinical programs and PHP in liver-dominant metastatic uveal melanoma.

Are Medical Stocks Lagging Delcath Systems (DCTH) This Year?

Zacks Investment Research · 15 Sept 2026neutral

The article compares the year-to-date performance of Delcath Systems (DCTH) and Encompass Health (EHC) against their sector.

Why it matters — A DCTH watcher would care because it shows how the company's stock has performed relative to its sector so far this year.

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 11 Sept 2026neutral

Delcath Systems announced that it granted Restricted Stock Units to four newly hired employees as material inducements under Nasdaq Listing Rule 5635(c)(4), with the grants totaling 34,000 RSUs. The equity awards were previously approved by the Company's Compensation Committee and relate to individuals whose employment commenced in July or August 2026.

Why it matters — This discloses new equity compensation tied to recent hires, which a Delcath watcher would consider relevant to share dilution and employee recruitment incentives.

FAQ

Frequently asked questions about DCTH stock

What is the DCTH stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Delcath Systems, Inc. have a median 12-month price target of $22, with estimates ranging from $21 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DCTH stock a buy right now?

Of the 5 analysts covering Delcath Systems, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Delcath Systems, Inc. 96 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DCTH?

As at 31 Oct 2026, Delcath Systems, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (100 of 100).

Will DCTH stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +56.7% from the last close, and Ticker Nerd's factor model ranks Delcath Systems, Inc. 96 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DCTH stock forecast for 2030?

No analyst covering Delcath Systems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DCTH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $32 over the next 12 months.

How has DCTH stock performed over the past year?

Delcath Systems, Inc. returned +49.4% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Delcath Systems, Inc. do?

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.

What is the latest news on DCTH?

The most recent item we track (Business Wire, 27 Oct 2026): "Delcath Systems to Participate in Upcoming Investor Conferences". Delcath Systems announced that management will attend the UBS Global Healthcare Conference on November 10, 2026, in Palm Beach Gardens, and Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026, in New York. The excerpt also begins listing another conference but does not provide its details.

Company

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company develops and commercializes drug-device therapies designed to deliver high-dose chemotherapy directly to the liver while limiting systemic exposure and related side effects. Its current product portfolio includes HEPZATO KIT in the United States and CHEMOSAT in Europe, both used in hepatic delivery procedures for liver cancer care. Delcath Systems serves specialized oncology centers and medical professionals that treat patients with liver tumors, positioning its technologies within the broader medical device and specialty pharmaceutical markets. Headquartered in Queensbury, New York, Delcath Systems plays a focused role in targeted cancer treatment by combining pharmaceutical and device-based approaches for liver-directed therapy.

CEO Mr. Gerard J. Michel MBA, MS · 156 employees · United States · https://www.delcath.com